Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Roivant Sciences Ltd.ROIV · Entity 3185 | Chief Accounting Officer | September 20, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Roivant Sciences Ltd.
Report date September 20, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 106,419 |
Reported balance
After 2026-09-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-20 · Tax withholding · Disposed 3,880 · Balance 106,419 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
F2: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2026 Filed Sep 23, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 3,880 | $39.77 | $154,307.60 |
DisclosureSEC source: 0001140361-26-037363 · form4.xml · nonDerivative · entry 1 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,419 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| June 20, 2026 Filed Jun 24, 2026 01:16 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 3,582 | $31.43 | $112,582.26 |
DisclosureSEC source: 0001635088-26-000067 · wk-form4_1782263780.xml · nonDerivative · entry 1 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,782 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:26 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 27,157 | $0.00 Strike: $29.08 | $0.00 |
DisclosureSEC source: 0001635088-26-000042 · wk-form4_1776896770.xml · derivative · entry 2 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,157 Underlying: Common Shares · 27,157 shares Expires 2036-04-19 F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2026. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in thirty-six (36) successive equal monthly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through each applicable vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:26 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 29,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001635088-26-000042 · wk-form4_1776896770.xml · nonDerivative · entry 1 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,364 F1 · shares: Reflects an award of restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2026. These RSUs vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in twelve (12) successive equal quarterly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through each applicable vesting date. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 13,538 | $28.37 | $384,073.06 |
DisclosureSEC source: 0001140361-26-014301 · form4.xml · nonDerivative · entry 1 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,191 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $28.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 23:07 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 14,526 | $27.70 | $402,370.20 |
DisclosureSEC source: 0001635088-26-000029 · wk-form4_1774393670.xml · nonDerivative · entry 1 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,729 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 20, 2025 Filed Mar 25, 2025 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 115,108 | $0.00 Strike: $10.97 | $0.00 |
DisclosureSEC source: 0001140361-25-010119 · form4.xml · derivative · entry 2 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,108 Underlying: Common Shares · 115,108 shares Expires 2035-03-19 F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of February 20, 2025. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in thirty-six (36) successive equal monthly installments thereafter, subject to the reporting person's Continuous Service through each applicable vesting date. Read SEC document |
| March 20, 2025 Filed Mar 25, 2025 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 112,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-010119 · form4.xml · nonDerivative · entry 1 Humes Jennifer · CIK 0002058012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,255 F1 · shares: Award of restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of March 20, 2025. These RSUs vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in twelve (12) successive equal quarterly installments thereafter, subject to the reporting person's Continuous Service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.